API, Inc. Asbestos Settlement Trust

ANNUAL REPORT OF THE TRUSTEE, 2020

API, INC. ASBESTOS SETTLEMENT TRUST

June 21, 2021

TO: Trust Advisor, API, Inc. Asbestos Settlement Trust Michael R. Strom SIEBEN POLK, PA Eagan Woods Office Center 2600 Eagan Woods Drive, Suite 50 Eagan, Minnesota 55121-1170

> Settlor, API, Inc. Asbestos Settlement Trust API, INC, c/o API GROUP, INC. c/o Chief Executive Officer 1100 Old Highway 8 NW New Brighton, MN 55112

This Annual Report has been prepared by the undersigned as Trustee of the API, Inc. Asbestos Settlement Trust (the "Trust"), pursuant to Sections 2.2 (b), and (c) of the First Amended API, Inc. Asbestos Settlement Trust [Trust] Agreement ("Trust Agreement"). Those sections of the Trust Agreement require the Trustee to prepare and submit an Annual Report containing the Trust's financial statements, auditor's opinion, and summary of type and number of claims to the Trust during the prior year, all as more fully described in those sections of the Trust Agreement.

This Report is the Trustee's Annual Report for 2020.

The Trust has retained the accounting firm of HG&K, Ltd. of Minneapolis, Minnesota, as the Trust's auditors, to prepare the Financial Statements, and to issue a fairness opinion as to those Financial Statements for 2020. Pursuant to that engagement, HG&K, Ltd. has completed both the Financial Statements, and has issued its Independent Auditor's Report regarding those Statements.

The 2020 Financial Statements are attached as Exhibit A.

The Trust has made payments on Claims during 2020. Payments on Claims made by the Trust in 2020 are:

ANNUAL REPORT OF THE TRUSTEE, API, INC. ASBESTOS SETTLEMENT TRUST June 18, 2021
Page 2

1) Current Direct Asbestos Claims paid during 2020 as submitted and approved pursuant to Section V4.1 of the Trust's Trust Distribution Procedures ("TDPs")

The summary of payments made to new Current Direct Asbestos Claims in 2020 is attached as Exhibit B.

2) Current Direct Asbestos Claims receiving supplemental payments pursuant to Paragraph 4.3 of the API Trust Distribution Procedures ("TDPs"), in order to bring all prior approved Claims to a payment level equivalent to the current Payment Sum Percentage of the Allowed Liquidated Value of thirty-seven percent (37%) for all approved Claims approved on or after July 1, 2020.

The summary of supplemental payments made to Current Direct Asbestos Claims in 202 is attached as Exhibit C.

This Annual Report is submitted solely for the purposes required in the Trust Agreement, and is not intended, nor should it be construed, as legal advice from the Trustee, or the Trust, to Claimants, Claimants' counsel, or others.

This Annual Report has this day been filed with the Office of the United States Trustee for the District of Minnesota, as described by Section 2(d) of the Trust Agreement, and by Paragraph 43 of the Order Confirming Third Amended Plan of Reorganization of A.P.I., Inc. (November 21, 2005) As Modified at Confirmation, dated December 6, 2005, Case No. BKY 05-30073-GFK.

API, INC. ASBESTOS SETTLEMENT TRUST

Robert D. Brownson TRUSTEE Minneapolis, Minnesota June 21, 2021

API, INC. ASBESTOS SETTLEMENT TRUST MINNEAPOLIS, MINNESOTA

AUDITED FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2020 and 2019

TABLE OF CONTENTS

INDEPENDENT AUDITOR'S REPORT

| STATEMENTS OF NET CLAIMANTS' EQUITY | 1 |
|--|--------|
| STATEMENTS OF CHANGES IN NET CLAIMANTS' EQUITY | 2 |
| STATEMENTS OF CASH FLOWS | 3 |
| NOTES TO FINANCIAL STATEMENTS | 4 - 11 |



Accountable.

Gregory D. Uphoff, CPA, CVA Loran W. Hillesheim, CPA Eric J. Hermanson, CPA

Dylan P. Abernathey, CPA Rachel M. Cheney Amy J. Dullum Timothy P. Jacobs, CPA Daniel D. Jorgenson, CPA Andrea R. Kulig, CPA Chris M. Schadow, CPA Lynn M. Tannler, CPA

Special Counsel
Lowell J. Gordon, CPA
Larry Messerli, CPA

INDEPENDENT AUDITOR'S REPORT

To the Trustee API, Inc. Asbestos Settlement Trust Minneapolis, Minnesota

Report on the Financial Statements

We have audited the accompanying special-purpose financial statements of API, Inc. Asbestos Settlement Trust which comprise the statements of net claimants' equity as of December 31, 2020 and 2019 and the related statements of changes in net claimants' equity and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these special-purpose financial statements in accordance with the special-purpose basis of accounting utilized by the Trust, described in Note 2. This includes determining that the special-purpose basis of accounting is an acceptable basis for the preparation of the financial statements in the circumstances. Management is also responsible for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Trust's preparation and fair presentation of the financial statements in order to design audit procedures that are

5850 Opus Parkway Suite 100 Minnetonka, MN 55343 Phone 952-979-1140 Fax 952-979-1160 www.hgkcpa.com

Member of
Minnesota Society
of Certified Public

American Institute
of Certified Public

appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Trust's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, net claimants' equity of API, Inc. Asbestos Settlement Trust as of December 31, 2020 and 2019 and the related changes in net claimants' equity and cash flows for the years then ended, in accordance with the special-purpose method of accounting described in Note 2.

Basis of Accounting

As described in Note 2, these financial statements were prepared on a special-purpose basis of accounting and are not intended to be a presentation in conformity with accounting principles generally accepted in the United States of America. The special-purpose basis of accounting has been used in order to present the amount of equity available to current and future claimants. Our opinion is not modified with respect to this matter.

Restriction on Use

Our report is intended solely for the information and use of the Trustee, the Legal Representative, the Trust Advisor, the beneficiaries of the Trust and the United States Bankruptcy Court for the District of Minnesota and is not intended to be and should not be used by anyone other than these specified parties. This restriction is not intended to limit distribution of this report, which, upon filing with the United States Bankruptcy Court for the District of Minnesota, is a matter of public record.

HG&K, LTD.

Certified Public Accountants Minnetonka, Minnesota

June 16, 2021

API, INC. ASBESTOS SETTLEMENT TRUST STATEMENTS OF NET CLAIMANTS' EQUITY DECEMBER 31, 2020 AND 2019

| | | 2020 | | 2019 |
|---|------|-------------------------------|------|---------------------------|
| ASSETS: | | | | |
| Current Assets: Cash and cash equivalents Note receivable, current portion Prepaid expenses | \$ | 632,641 1,300,000 6,983 | \$ | 573,993 1,300,000 - |
| Investments | | 5,786,039 | | 6,817,552 |
| Total current assets | _\$_ | 7,725,663 | _\$ | 8,691,545 |
| Other Assets: | | | | |
| Note receivable, net of current portion | \$ | 6,825,000 | \$ | 8,125,000 |
| Total other assets | \$ | 6,825,000 | \$ | 8,125,000 |
| Total Assets | _\$_ | 14,550,663 | _\$_ | 16,816,545 |
| LIABILITIES: | | | | |
| Current Liabilities: Accounts payable | \$ | 18,457 | \$ | 114,709 |
| Claims payable | | 27,489 | | 453,303 34,000 |
| Claims processing fees payable Total current liabilities | \$ | 33,000 78,946 | \$ | 602,012 |
| Total current nabilities | _Ψ_ | 70,040 | _Ψ | 002,012 |
| NET CLAIMANTS' EQUITY | _\$_ | 14,471,717 | \$ | 16,214,533 |

See Independent Auditor's Report and Notes to Financial Statements.

API, INC. ASBESTOS SETTLEMENT TRUST STATEMENTS OF CHANGES IN NET CLAIMANTS' EQUITY FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

| | 2020 | 2019 |
|---|---|--|
| Additions: | | |
| Interest income Dividend income Gain on investments | \$ 77,430 72,853 702,746 | \$ 146,449 27,129 648,827 |
| Claim processing fees and miscellaneous income Total additions | \$ 1,039 854,068 | \$ 390 822,795 |
| Deductions: Accounting fees Bank charges Foreign tax paid Insurance Investment management fees Legal fees Office expenses Trustee fees Legal Representative fees Total deductions | \$ 38,803 210 987 6,727 49,193 2,072 241 108,137 48,000 254,370 | \$ 35,649 223 241 4,747 40,857 18,764 7,216 122,900 50,100 280,697 |
| Change in net claimants' equity | \$ 599,698 | \$ 542,098 |
| Net claimants' equity, beginning of period | 16,214,533 | 16,669,659 |
| Contributions to net claimants' equity | - | 1,075,000 |
| Distributions from net claimants' equity | (2,342,514) | (2,072,224) |
| Net claimants' equity, end of period | \$ 14,471,717 | \$ 16,214,533 |

API, INC. ASBESTOS SETTLEMENT TRUST STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

| | | 2020 | | 2019 |
|---|------|-----------|------|-----------|
| CASH INFLOWS: | | | | |
| Investment income | \$ | 199,496 | \$ | 236,900 |
| Proceeds from note receivable | | 1,300,000 | | 1,300,000 |
| Proceeds from sale of investments | | 4,323,632 | | 3,798,472 |
| Proceeds from insurance settlement | | _ | | 1,075,000 |
| Receipt of claim search fees and miscellaneous income | | 1,039 | | 390 |
| Receipt of claim processing payments | | 5,500 | | 11,500 |
| | _\$_ | 5,829,667 | _\$_ | 6,422,262 |
| CASH OUTFLOWS: | | | | |
| Distributions to claimants | \$ | 2,755,895 | \$ | 1,595,873 |
| Disbursements for trust operating expenses | | 272,794 | | 279,092 |
| Litigation expenses related to claimants' equity | | 97,245 | | 26,466 |
| Purchases of investments | | 2,638,585 | | 4,637,410 |
| Refund of claim processing payments | | 6,500 | | 8,500 |
| | \$ | 5,771,019 | _\$ | 6,547,341 |
| | | | | |
| NET (DECREASE) IN CASH AND CASH EQUIVALENTS | \$ | 58,648 | \$ | (125,079) |
| CASH AND CASH EQUIVALENTS, beginning of period | | 573,993 | | 699,072 |
| CASH AND CASH EQUIVALENTS, end of period | \$ | 632,641 | \$ | 573,993 |

NOTE 1. DESCRIPTION OF THE TRUST

The API, Inc. Asbestos Settlement Trust (the Trust), organized pursuant to the laws of the State of Minnesota, was established according to the Third Amended Plan of Reorganization of API, Inc. as modified (the Plan). The Trust was formed to assume all asbestos claims against API, Inc., whether now existing or arising at any time hereafter, and to use the Trust's assets and income to pay holders of allowed asbestos claims in accordance with the Plan and Trust Agreement. The Trust's funding is dedicated solely to the settlement of asbestos health claims and the related costs, as defined in the Plan. The Trust was consummated on February 5, 2007.

The Trust was initially funded with cash, a promissory note from API, Inc., rights to proceeds from asbestos insurance policies and insurance settlement rights.

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Trust's financial statements are prepared using special-purpose accounting methods that differ from accounting principles generally accepted in the United States of America. The special-purpose accounting methods were adopted in order to present the amount of equity available for payment of current and future claims and operating expenses of the Trust. Since the accompanying special-purpose financial statements are not based on accounting principles generally accepted in the United States of America, accounting treatment by other parties for these same transactions may differ as to timing and amounts. These special-purpose accounting methods are as follows:

- (1) The financial statements are prepared using the accrual basis of accounting.
- (2) The funding received from API, Inc., API Group, Inc. and the insurance companies are added directly to net claimants' equity. The distributions to claimants and litigation expenses incurred in relation to additions to net claimants' equity are deducted directly from net claimants' equity. These funds do not represent income or expenses of the Trust.
- (3) Non-interest bearing notes have not been discounted to present value.
- (4) Costs of non-income producing assets, which will be exhausted during the life of the Trust and are not available for satisfying claims, are expensed as they are incurred. These items include costs of computer hardware and software.

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Basis of Presentation (continued)

- (5) Investments are recorded at fair value. All interest and dividend income is included in interest and dividend income on the statements of changes in net claimants' equity. Realized and unrealized gains and losses are reflected on the statements of changes in net claimants' equity.
- (6) The Trust does not record a deferred tax asset for net operating loss carryforwards or a deferred tax asset or liability arising from unrealized gains or losses on securities. For the years ended December 31, 2020 and 2019, the net operating loss carryforward available for use in future years was \$4,726,783 and \$4,762,250, respectively. The net operating loss carryforwards begin to expire in the year ending December 31, 2027.
- (7) Payments for services to be received over an extended period in the future are recorded as expenses when incurred as these amounts are no longer available for the payment of claims.

Adoption of Accounting Standard

During the year ended December 31, 2020, the Trust adopted Accounting Standards Update 2018-13, *Fair Value Measurement (Topic 820)*. This Update improved the disclosure requirements for fair value measurements.

Cash and Cash Equivalents

The Trust considers unrestricted currency, demand deposits, and certificates of deposit with an initial maturity of three months or less to be cash and cash equivalents.

Fair Value of Investments

The Trust measures its investments at fair value. Fair value is defined as the price at which an asset could be exchanged in a current transaction between knowledgeable and willing parties.

Fixed Assets

The cost of non-income producing assets that will be exhausted during the life of the Trust and are not available for satisfying claims are expensed as incurred. Since inception of the Trust through December 31, 2020, the cost of fixed assets expensed includes website development costs of \$4,003.

Claims Payable

Claims payable on the statements of net claimants' equity reflect claims approved but unpaid as of December 31 of each year.

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Estimates

The preparation of financial statements in conformity with the special-purpose accounting methods described above requires Trust management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of additions and deductions to net claimants' equity during the reporting periods. Accordingly, actual results may differ from those estimates.

Date of Trustee Review

In preparing these financial statements, the Trust has evaluated events and transactions for potential recognition or disclosure through June 16, 2021, the date the special-purpose financial statements were available to be issued.

NOTE 3. NOTE RECEIVABLE

Note receivable as of December 31, 2020 and 2019 consisted of a promissory note from API, Inc. The original face value of the note was \$26,000,000. The note calls for eighty quarterly payments of \$325,000 and is due in full in March 2027. The note bears no interest. The note is secured by 51 percent of the common shares of API, Inc. and certain other assets of API, Inc. As of December 31, 2020 and 2019, the note was receivable as follows:

| | 2020 | 2019 |
|----------------------------|--------------|-----------------|
| Receivable within one year | \$ 1,300,000 | \$ 1,300,000 |
| Receivable in future years | 6,825,000 | 8,125,000 |
| · | \$ 8,125,000 | \$ 9,425,000 |

NOTE 4. FAIR VALUE MEASUREMENTS

Investments recorded at fair value are categorized using the defined hierarchical levels directly related to the amount of subjectivity associated with the inputs to value an asset. Level 1 inputs consist of quoted prices in active markets for identical assets and have the highest priority. Level 2 inputs consist of quoted prices for similar instruments in active markets or quoted prices for identical or similar investments in markets that are not active markets. Level 2 inputs also consist of valuation techniques for which significant assumptions are observable in the market or can be corroborated by observable market data. Level 3 inputs consist of unobservable inputs that can not be corroborated by observable market data and typically reflect Trust management's estimate of fair value.

NOTE 4. FAIR VALUE MEASUREMENTS (continued)

The Trust uses appropriate valuation techniques based on the available inputs to measure the fair value of investments. When available, the Trust measures fair value using Level 1 inputs because they generally provide the most reliable evidence of fair value. Level 3 inputs are used only when Level 1 or Level 2 inputs were not available. The Trust did not have any Level 3 investments for the years ended December 31, 2020 and 2019. Fair values of assets measured on a recurring basis at December 31, 2020 and 2019 are as follows:

| | | Fair Value at Decen | |
|---|--|---|---|
| | Fair Value | <u>Using Inputs Cor</u> Level 1 | Level 2 |
| Municipal Bonds: S&P Rated AAA S&P Rated AA S&P Rated A Total Municipal Bonds | \$ 320,316 940,348 264,582 1,525,246 | | \$ 320,316 940,348 264,582 1,525,246 |
| Common Stock: Consumer discretionary Consumer staples Energy Finance Health care Industrials/Materials Information technology Real estate Telecommunications Utilities Total Common Stock | 755,702 381,170 44,062 454,802 473,281 478,833 1,142,569 76,990 394,271 59,113 4,260,793 | \$ 755,702 381,170 44,062 454,802 473,281 478,833 1,142,569 76,990 394,271 59,113 4,260,793 | |
| Total Investments | \$ 5,786,039 | \$ 4,260,793 | <u>\$ 1,525,246</u> |
| | _Fair Value | Fair Value at Decer Using Inputs Co | |
| Municipal Bonds: S&P Rated AAA S&P Rated AA S&P Rated A Total Municipal Bonds | \$ 1,130,531 1,509,234 746,447 3,386,212 | | \$ 1,130,531 1,509,234 746,447 3,386,212 |
| Common Stock: Consumer discretionary Consumer staples Energy Finance | 461,707 394,932 94,734 379,102 | \$ 461,707 394,932 94,734 379,102 | |

NOTE 4. FAIR VALUE MEASUREMENTS (continued)

| | | Fair Value at Dece Using Inputs C | |
|---------------------------|--------------|--------------------------------------|---------------------|
| | Fair Value | Level 1 | Level 2 |
| Common Stock (continued): | | | |
| Health care | 361,377 | 361,377 | |
| Industrials/Materials | 385,782 | 385,782 | |
| Information technology | 754,859 | 754,859 | |
| Real estate | 66,188 | 66,188 | |
| Telecommunications | 442,773 | 442,773 | |
| Utilities | 89,886 | <u>89,886</u> | |
| Total Common Stock | 3,431,340 | 3,431,340 | |
| Total Investments | \$ 6,817,552 | \$ 3,431,340 | <u>\$ 3,386,212</u> |

Level 2 Fair Value Measurements:

The Trust uses a market approach to value the Level 2 investments. The value of municipal bonds are based on institutional bond quotes and various market and industry inputs. Municipal bonds are presented by S&P bond rating.

NOTE 5. NET CLAIMANTS' EQUITY

The contributions to claimants' equity were comprised of the following at December 31, 2020 and 2019:

| | 2020 | 2019 |
|----------------------------|--------|--------------|
| Insurance case settlements | \$ -0- | \$ 1,075,000 |

The distributions from claimants' equity were comprised of the following at December 31, 2020 and 2019:

| | 2020 | | 2019 |
|---|-----------------|----|-----------|
| Distributions to claimants | \$ 2,330,081 | \$ | 2,049,175 |
| Legal fees related to claimants' equity | 12,433 | | 23,049 |
| - , , | \$ 2,342,514 | \$ | 2,072,224 |

The distributions to claimants represents a payment sum percentage of 37 and 35 percent of the allowed liquidated value per claimant as of December 31, 2020 and 2019, respectively, per the Trust Distribution Procedures. The Trust Distribution Procedures allow this percentage to be evaluated at least once per year by the Trustee, the Legal Representative and the Trust Advisor (Advisory Committee). Distributions prior to October 1, 2010 also included enhanced payments for exigent health, extraordinary or extreme hardship claims, if applicable, as determined by the Trustee. As of October 1, 2010, claims could be filed and approved as exigent health, extraordinary or extreme hardship claims, but the enhanced payments are deferred until the Trust is financially capable of making enhanced payments.

NOTE 6. INVESTMENT INCOME

Investment income consists of:

| | 2020 | 2019 |
|---------------------------------------|-------------------|-------------------|
| Realized gain (loss) on investments | \$ 177,071 | \$ 167,175 |
| Unrealized gain (loss) on investments | 525,675 | 481,652 |
| Gain (loss) on investments | \$ 702,746 | \$ 648,827 |
| , , | | |
| Total interest income | \$ 126,643 | \$ 209,771 |
| Less: bond premium amortization | (49,213) | (63,322) |
| Interest income | <u>\$ 77,430</u> | <u>\$ 146,449</u> |
| | | |
| Dividend income | <u>\$ 72,853</u> | <u>\$ 27,129</u> |
| | | |
| Total investment income | <u>\$ 853,029</u> | <u>\$ 822,405</u> |

NOTE 7. INCOME TAXES

For federal income tax purposes, API, Inc. has elected for the qualified assets of the Trust to be taxed as a Designated Settlement Fund (DSF). Income and expenses associated with the DSF are taxed in accordance with Section 468B of the Internal Revenue Code. As of 2020, the federal statutory income tax rate for the DSF is thirty seven percent.

The Advisory Committee believes the Trust is operating in a manner so as to continue to qualify as a Designated Settlement Fund. The Trust recognizes potential interest and penalties pertaining to income tax related issues, if any, as income tax expense. During the years ended December 31, 2020 and 2019, no such interest or penalties were recognized.

The Trust Advisory Committee evaluates all tax positions and makes a determination regarding their likelihood of being upheld under review. For the years ended December 31, 2020 and 2019, the Trust did not have uncertain tax positions for which they recorded a tax liability.

NOTE 8. RELATED PARTY TRANSACTIONS

During the years ended December 31, 2020 and 2019, the Trust incurred legal fees of \$2,072 and \$2,044, respectively, from the firm in which the Trustee is an owner. These amounts are included in legal fees for the years ended December 31, 2020 and 2019 on the statements of changes in net claimants' equity.

NOTE 8. RELATED PARTY TRANSACTIONS (continued)

During the years ended December 31, 2020 and 2019, the Trust incurred fees of \$156,137 and \$173,000, respectively, from members of the advisory committee in their roles as Trustee, Legal Representative and Trust Advisor. Of these amounts, \$18,457 and \$22,098 are included in accounts payable on the statements of net claimants' equity as of December 31, 2020 and 2019, respectively. The Trust Advisor is a principal member of the law firm representing numerous claimants.

NOTE 9. INSURANCE SETTLEMENTS

In January 2008, settlement agreements were approved by the courts with seven insurance companies. The insurance settlements were received during the year ended December 31, 2008.

Pursuant to the settlement agreement with one of the insurance companies, the immediate cash settlement of seven million dollars was paid to the Trust in 2008 and was nonrefundable. The remainder of the aggregate settlement amount is payable to the Trust upon certain criteria being met. Upon such time that the insurance company reimbursement obligation for all qualified asbestos claims related to the insurance carrier exceeds the original cash settlement amount of seven million dollars, the insurance carrier is obligated to make additional settlement payments to the Trust, up to a maximum of an additional eleven million dollars. As of December 31, 2020, the reimbursement obligation for the insurance carrier was approximately \$5,099,200, which is below the original cash settlement amount. The amount of the potential additional settlement funds is undeterminable at this time and has not been reflected in the financial statements.

NOTE 10. INSURANCE CASE SETTLEMENTS

In prior years, various claims had been presented to the Liquidator for Home Insurance Company. During the year ended December 31, 2012, the Trust reached a settlement agreement with the Liquidator for Home Insurance Company. The Trust's claim had been accepted as a Class II claim in the liquidated amount of \$21,500,000. During the years ended December 31, 2020 and 2019, the Trust received \$0 and \$1,075,000, respectively, from their settlement claim. As of December 31, 2020, the Trust has received \$6,450,000 of their approved claim (30 percent of the settlement amount). As Home Insurance Company is in liquidation, it is anticipated that the Trust will not receive the entire settlement amount. The amount of the potential additional receipts under the settlement is undeterminable at this time and has not been reflected in the financial statements.

NOTE 11. CONCENTRATIONS AND CREDIT RISK

The Trust maintains cash balances at various financial institutions. At times during the years ended December 31, 2020 and 2019, the Trust had significant concentrations of credit risk as a result of maintaining its bank accounts with aggregate balances in excess of the federal insurance coverage of \$250,000.

The Trust has a note receivable from API, Inc. This note is secured by 51 percent of the common stock of API, Inc. and certain other assets of API, Inc. The amount of loss the Trust would occur if API, Inc. should default is not determinable.

The Trust invests in professionally managed portfolios. Such investments are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the Trust's investment account balances and the amounts reported in the special-purpose statements of net claimants' equity and statements of changes in net claimants' equity.

NOTE 12. LEGAL DECISION

The Trust was a respondent in a lawsuit where the appellant was seeking recovery of a portion of the Home Insurance Company settlement proceeds received by the Trust. In March 2019, Ramsey County District Court determined that the appellant was owed \$84,000 for their services to the Trust. The appellant appealed this decision to the Minnesota Court of Appeals, which affirmed the District Court's ruling in December 2019.

The settlement amount of \$84,000 determined by the District Court was included in accounts payable on the statements of net claimants' equity as of December 31, 2019.

NOTE 13. COVID-19 RELATED CONSIDERATIONS

The Trust is closely monitoring the impact of the pandemic of the novel strain of coronavirus, known as COVID-19, on all aspects of the Trust's operations. While the Trust did not incur significant disruptions in its operations during the year ended December 31, 2020 from COVID-19, due to the uncertainties surrounding the COVID-19 pandemic, we are unable to predict the impact on our net claimants' equity, the changes in net claimants' equity and cash flows in future periods.

Current Direct Second Injury Claims Paid in 2020

| Nc# Claimant | Decedent | State | Disease | Payment 1 | Date Paid |
|---------------------------|-------------------------|--------|----------------------------|--------------|------------|
| 751 Wudinich, Cindy (Ext) | Wudinich, Mathew D. | NΜ | I - Malignant Mesothelioma | \$110,687.50 | 2/11/2020 |
| 755 Tourville, John R. | | Z | I - Malignant Mesothelioma | \$110,687.50 | 2/11/2020 |
| 756 Lyons, Robert L. | | Z | V - Pleural | \$10,552.50 | 2/11/2020 |
| 757 Johnson, Paul W. | | Z | I - Malignant Mesothelioma | \$110,687.50 | 2/11/2020 |
| 758 Warner, Melanie L. | | N Σ | I - Malignant Mesothelioma | \$110,687.50 | 2/11/2020 |
| 760 Borchert, Clayton J. | | NΣ | I - Malignant Mesothelioma | \$110,687.50 | 2/11/2020 |
| 761 Heroff, Richard K. | | NΣ | II - Lung Cancer | \$50,708.50 | 11/17/2020 |
| 764 Hammes, Sharon (Adm) | Hammes, Leonard Frances | Z | I - Malignant Mesothelioma | \$117,012.50 | 11/17/2020 |
| 766 Jenniges, Mary (Adm) | Jenniges, Paul R. | NΣ | I - Malignant Mesothelioma | \$117,012.50 | 9/8/2020 |
| 767 Biernat, Eileen J. | | NΣ | I - Malignant Mesothelioma | \$117,012.50 | 9/8/2020 |
| 768 Sluyter, Gregory | | NΣ | I - Malignant Mesothelioma | \$117,012.50 | 11/17/2020 |
| 769 Forciea, Donald J. | | N Σ | I - Malignant Mesothelioma | \$117,012.50 | 11/17/2020 |
| 770 Kosmides, Susan | | Z Z | II - Lung Cancer | \$50,708.50 | 12/22/2020 |

TOTAL \$1,250,469.50

| Nc# | <u>Claimant</u> Buche, Ralph J. | Decedent | State MN | <u>Disease</u> I - Malignant Mesothelioma | <u>Payment</u> \$6,325.00 | <u>Date Paid</u> 8/4/2020 |
|-----|------------------------------------|------------------------|-------------|--|------------------------------|------------------------------|
| 350 | Schlossmacher, Ann (Trustee) | Schlossmacher, Robert | Z Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 351 | Hogan, Anna Mae (Trustee) | Hogan, Vernon | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 353 | Kotten, Mary (Trustee) | Kotten, Jerome J. | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 354 | Rutten, John T. | | Ν Ν | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 355 | lozzo, John | | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 357 | White, Robert Michael | | SD | I - Malignant Mesothelioma | \$2,341.74 | 8/4/2020 |
| 358 | Cormier, Gregory (Trustee) | Comier, Richard F. | Z Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 359 | Ruelle, John C. | | Z Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 360 | Rensch, Amy (Trustee) | Barfknecht, Ray J. | Z Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 361 | Karsnia, Michael C. | | Z Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 362 | Taylor, LeRoy J. | | Z Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 363 | Colvard, Jeanne (Trustee) | Colvard, Troy | Z Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 364 | Holton, Larry Gene | | Z Z | V - Pleural | \$603.00 | 8/4/2020 |
| 366 | Fellman, Mark J. (Trustee) | Bohn, Willard Eugene | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 367 | Farley, Joseph R. | | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 368 | Wahl, Marilyn (Trustee) | Wahl, Russell A. | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 369 | Kappes, James K. | | Z Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 370 | Buzick, Cheryl (Trustee) | Buzick, Arthur | ND | II - Lung Cancer | \$895.54 | 8/4/2020 |
| 371 | Engquist, Steven (Trustee) | Engquist, Cheryl | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 372 | Paulsen, Wayne G. | | Z Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 374 | Fritz, Wilfred Michael | | z Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 376 | Morrow, Ronald L., Jr. (Trustee) | Morrow, Ronald L., Sr. | z Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 377 | Fontaine, Donald T. | | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 378 | Weinner, David J. | | z Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 380 | Gorder, Raymond E. | | Z Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 381 | Blais, William D. | | z Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 382 | Ness, Bruce E. | | Z Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 383 | Palm, James E. | | Z Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 384 | Delsing, Michael D. | | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 385 | Froom, Donald C. | | Z Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 386 | Michels, Robert | | Z Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 387 | Chalkline, Harold | | Z Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 388 | Appert, Patrick A. | | ND | I - Malignant Mesothelioma | \$2,341.74 | 8/4/2020 |
| 389 | Huppertz, Theresa (Trustee) | Huppertz, Peter W. | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 390 | Husnick, Eugene P., Jr. | | z Z | V - Pleural | \$603.00 | 8/4/2020 |
| 391 | Dahlman, Christine (Trustee) | Westerson, David R. | z Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 392 | Carver, Maurice R. | | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |

| 467 N 468 R 469 P. 470 H | :- | | | | | 3 |
|-----------------------------------|---------------------------------|-------------------------|--------|----------------------------|------------|----------|
| | Nesset, Curtis | | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| | Rossbach, Arthur | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| | Panger, Steven M. (Trustee) | Panger, Gale R. | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| | Hollenhorst, Roger (Trustee) | Hollenhorst, Julius F. | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 481 B | Brown, Robert W. | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 482 A | Anderson, Anita (Trustee) | Anderson, Dale Gilbert | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 483 K | Kobus, Joseph W. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 485 Lo | Loutzenhiser, Edward | | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 486 R | Rudan, Brenda (Adm) | Kelly, Maureen | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 487 So | Schumann, Sherry (Trustee) | Beckett, Everett Louis | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 488 G | Genise, Frank E. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 489 Si | Simmons, Audrey (Adm) | Simmons, Peter A. | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 490 G | Gibson, Tina Marie (Trustee) | Trettel, David E. | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 491 B | Beier, Fred N. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 493 B | Brausen, Ann W. (Trustee) | | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 494 H | Hagen, James O. | | N | I - Malignant Mesothelioma | \$2,341.74 | 8/4/2020 |
| 495 N | Malinowski, Joseph | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 496 B | Benton, Melvin | | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 497 K | Krech, Douglas M. | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 498 Si | St. Martin, Jerome | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 499 B | Bidwell, Lois (Trustee) | Bidwell, George W., Sr. | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 500 R | Rebel, James L. | | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 502 K | Kling, Steven | | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 503 St | Strot, Donald V. | | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 504 C | Coleman, Wayne | | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 505 W | Watson, Frederick | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 506 Li | Lilledahl, Barbara M. (Trustee) | Lilledahl, Charles R. | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 507 To | Foninato, Bruno | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 508 P | Pearson, Dennis H. | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 511 K | Kammier, Robert V. | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 512 Li | illedahl, Donald Ray | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| | -ePage, Raymond | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| | Karpesh, Mike | | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 515 SI | Skoglund, Eugene | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 516 W | Wolff, Gregory (Adm) | Wolff, Fred | SD | I - Malignant Mesothelioma | \$2,341.74 | 8/4/2020 |
| 517 G | Gorski, Edward | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 518 M | White, Judy (Trustee) | White, Dennis | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 519 Jc | Johnson, Gerald B. | | Z Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |

| NC# | Claimant | Decedent | State | Disease | Payment | Date Paid |
|-----|--|-------------------------|-------|----------------------------|------------|-----------|
| 520 | Burrell, Wayne R. | | Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 521 | Casale, Frank | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 522 | Lendacky, Joseph | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 523 | Crowley, Rosalie K. | | Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 525 | Morrison, Merle | | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 526 | Foerster, William D., Jr. | | Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 529 | Kittel, Dawn (Trustee) | Plante, Kenneth E. | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 530 | Teske, Thomas (Trustee) | Teske, Chester | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 531 | Cheesebrow, Nicholas T., Jr. (Trustee) | Cheesebrow, Nicholas T. | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 532 | Durbin, Donald | | Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 533 | McKinney, Scott (Trustee) | McKinney, William W. | Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 534 | Svaleson, Stephen | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 535 | Casselman, Mary F. | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 236 | Dreyling, Arthur P. | | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 537 | Most, Larry R. | | Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 538 | Hill, Randall (Trustee) | Hill, Howard R. | Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 539 | Kratzke, Dolores (Trustee) | Kratzke, Bennard J. | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 540 | Phillips, Patricia (Trustee) | Phillips, John W. | Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 541 | Peterson, North M. | | Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 542 | Anderson, Lance R. | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 543 | Gouin, Joseph | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 544 | Henke, Robert R. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 545 | Scholz, Robert W. | | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 546 | Moore, Stanley U. | | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 547 | Miller, James R. | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 548 | Gustafson, Andrea (Trustee) | Gustafson, Dale R. | Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 549 | Crnobrna, Robert J. | | Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 550 | Stacey, Louis R., Jr. | | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 551 | Banta, James L. | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 552 | Beringer, Deborah (Trustee) | Kolbeck, Joanne B. | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 553 | Hackler, Arnold (Trustee) | Hackler, Lloyd | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 554 | Deslich, Joseph | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 555 | Linc, Thomas | | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 556 | Brunner, Dolores (Trustee) | Brunner, Louis F. | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 557 | Crawford, Robert L. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 558 | Jelley, Hugh E. | | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 559 | Jasper, Joseph J. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 561 | Boyd, Audrey (Adm) | Welch, Vernon | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |

| NC# | Claimant | Decedent | State | Disease | Payment | Date Paid |
|-----|---------------------------|-----------------------|--------|----------------------------|------------|-----------|
| 562 | Psihos, Adrienne (Adm) | Psihos, George | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 563 | Thiel, Douglas (Trustee) | Thiel, Norman M. | Z Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 564 | Kelly, Lois | | Z Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 292 | Bertrand, Jacqueline | | Z Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 266 | Meyers, Anita (Trustee) | Schiller, Joseph J. | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 267 | Anderson, Thomas E. | | Z Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 268 | Hanscom, Robert B. | | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 269 | Elliott, Lawrence (Adm) | Wendt, Gladys | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 570 | Erdman, Daniel R. | | Z Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 571 | Romslo, Michael | | Z Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 573 | Bush, Mark (Adm) | Bush, Thomas W. | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 574 | Olson, Clyde | | ZΣ | V - Pleural | \$603.00 | 8/4/2020 |
| 216 | Aeschliman, Roy | | ZΣ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 577 | Bowman, Paul E. (Trustee) | Bowman, Rosalyn V. | ZΣ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 578 | Nelson, John R. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 579 | Baker, James M. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 280 | Scully, Patrick | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 581 | Dumond, Joyce (Trustee) | Dumond, Norvall | ZΣ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 582 | Gagnier, Arthur D. | | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 583 | Tate, Judith (Trustee) | Tate, Gary D. | ZΣ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 584 | Rabe, Harley | | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 585 | Caspers, Mark E. | | ZΣ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 286 | Hadd, Richard G. | | ZΣ | V - Pleural | \$603.00 | 8/4/2020 |
| 587 | Busse, Michael S. | | ZΣ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 588 | French, Andrew (Trustee) | French, Jay R. | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 589 | Floyd, Denise (Adm) | Jones, Forrest D. | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 290 | Anderson, David J. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 592 | Reidt, Elroy J. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 593 | Johnson, Richard L. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 594 | Hendrickson, John W., Jr. | | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 262 | Tomczak, William | | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 296 | Ingalls, Yvonne | Ingalls, George Leroy | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 297 | Larson, Orville R. | | Z Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 298 | Mueller, Gerald | | ZΣ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 299 | Wilson, Edward J. | | ZΣ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 009 | Tate, Susan M. (Trustee) | Langenfeld, John T. | Z Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 601 | Roche, Donna (Adm) | Roche, Joseph L. | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 602 | Orum, Linda (Ext) | Orum, Ronald | Z Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| | | | | | | |

| Nc# Claimant | Decedent | State | Disease | Payment | Date Paid |
|--|------------------------|--------|----------------------------|------------|-----------|
| 603 Endres, John J. | | M | V - Pleural | \$603.00 | 8/4/2020 |
| 604 Danielson, Steven (Trustee) | Danielson, Robert L. | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 605 Nordgaard, Richard T. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 606 Fibison, George T. | | Z | V - Pleural | \$603.00 | 8/4/2020 |
| 607 Roslee, John A. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 608 Schaffer, John C. | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 609 Simonson, Howard H. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 610 Luzaich, Richard A. | | Ν Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 611 Mitchler, Rosemary (Adm) | Mitchler, John | M | I - Malignant Mesothelioma | \$2,341.74 | 8/4/2020 |
| 612 Edgette, Ray Charles | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 613 Johnson, Donald B. | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 614 Minogue, Michael R. | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 615 Walters, Gordon | | Z | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 616 Lauppe, Lorie (Trustee) | Baum, Delores P. | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 617 Kettner-Banse, Katherine (Trustee) | Kettner, Leo | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 620 Norring, Terrell | | Ν | V - Pleural | \$603.00 | 8/4/2020 |
| 621 Lamprecht, Ursula (Adm) | Lamprecht, Rudolf | Ν | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 623 McIntosh, Charles R. | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 624 Carlson, Craig (Adm) | Carlson, Arlene C. | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 626 Berglund, Larry | | N | V - Pleural | \$603.00 | 8/4/2020 |
| 627 Crewson, Thomas A. | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 629 Kust, John E. | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 630 Ash, Donald | | N | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 631 Clymer, Michael R. | | Ν N | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 632 Duresky, Ronald | | N | V - Pleural | \$603.00 | 8/4/2020 |
| 633 Jorgenson, Duane | | Z | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 635 Wicklund, Robert C. | | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 636 Rubedor, Mark | | Ν | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 643 Conda, Jenella (Trustee) | Conda, Ronald E. | Ν | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 645 Hruska, Lavern (Trustee) | Hruska, Joseph J. | Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 649 Thompson, Kathy (Adm) | Thompson, Robert James | Ν | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 650 Herlofsky, Gerald A. | | Ν N | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 651 Wappel, Andrew S. | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 653 Haack, Judith C. | | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 654 Turnberg, Dean M. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| • | | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| | Diercks, Roger E. | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 659 Wade, Vicki (Trustee) | Wade, William J. | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |

| Nc# Claimant | Decedent | State | Disease | Payment | Date Paid |
|----------------------------------|----------------------------|--------|----------------------------|------------|-----------|
| 660 Graves, Bruce | | MN | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 661 Krzoska, Leland | | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 662 Earney, Coralie (Adm) | Earney, Gregg A. | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 663 Lindbloom, Carol (Adm) | Lindbloom, Wayne | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 664 Nielsen, Donna (Adm) | Nielsen, Gary C. | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 665 Widdifield, Charlotte (Adm) | Widdifield, Allen K. | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 666 Swenson, Rick (Adm) | Swenson, Loretta D. | NΣ | l - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 667 Norberg, Olaf A. | | Ν N | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 668 Kantor, Lee (Adm) | Kantor, Elizabeth L. | Ν | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 669 Dyer, Charles L. | | Ν | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 671 Sabourin, Gary F. | | Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 672 Bergseth, John O. | | Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 673 Bistodeau, Gary | | Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 683 Pfeffer, Gerald P. | | Σ | V - Pleural | \$603.00 | 8/4/2020 |
| 684 Graham, William F. | | Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 685 Kerner, Richard J. (Trustee) | Kerner, Dennis H. | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 686 Hecker, Tonya M. (Adm) | Higson, Charles D. | Ν | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 688 Schmidt, John R. | | Ν | V - Pleural | \$603.00 | 8/4/2020 |
| 689 Scovil, Richard J. | | Ν Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 690 Kubitschek, Judith (Trustee) | Kubitschek, Robert J., Sr. | NΣ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 691 Jacobson, Charles (Trustee) | Duren, Eligius R. | NΜ | V - Pleural | \$603.00 | 8/4/2020 |
| 692 Skogstad, Arllan N. | | NΣ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 693 Price, Bryan (Trustee) | Price, Charles D., Sr. | NΜ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 694 Brickley, Marlene M. | | NΣ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 695 Stangl, Alfred M., Jr. | | Ν | V - Pleural | \$603.00 | 8/4/2020 |
| 696 Ohlquist, Maurice | | Ν | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 697 Witherill, Nicholas J. | | Σ | II - Lung Cancer | \$2,741.00 | 8/4/2020 |
| 698 Begin, Leo (Trustee) | Begin, Clifford A. | Σ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 699 Monzel, James M. | | NΣ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 700 Hall, Eleanor (Adx) | Hall, Leland W. | Ν Ν | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 701 Alcorn, Cindy J. | | NΣ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 703 Robinson, Charles William | | Ν Σ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 704 Vohler, Dennis | | NΣ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 705 Palmehn, Lawrence (Adm) | Palmehn, Lisa A. | NΕ | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 706 Lindhag, Alan E. | | NΜ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 707 Hanson, William J. | | NΣ | IV - Asbestosis | \$1,144.00 | 8/4/2020 |
| 708 Zirkle, Clarice (Adm) | Zirkle, Raymond E., Jr. | Ν | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |
| 709 Blais, George A., Sr. | | Z | I - Malignant Mesothelioma | \$6,325.00 | 8/4/2020 |

| | | \$6,325.00 8/4/2020 | | | | | |
|----------|----------------------------|----------------------------|--------------------|------------------|----------------------------|----------------------------|----------------------|
| Disease | I - Malignant Mesothelioma | I - Malignant Mesothelioma | | | I - Malignant Mesothelioma | I - Malignant Mesothelioma | |
| State | Σ | Z | ZΣ | MΝ | MΝ | Σ | ZΣ |
| Decedent | | | | | | | |
| Claimant | Grundeman, Ralph R. | Lehner, Kenneth O. | Tourville, John R. | Lyons, Robert L. | | Warner, Melanie L. | Borchert, Clayton J. |
| HC# | 753 | 754 | 755 | 756 | 757 | 758 | 209 |

\$1,334,840.05

TOTAL